Human monoclonal anti-phospholipid antibodies selectively bind to membrane phospholipid and beta2-glycoprotein I (beta2-GPI) on apoptotic cells. 2000

V Pittoni, and C T Ravirajan, and S Donohoe, and S J MacHin, and P M Lydyard, and D A Isenberg
Centre for Rheumatology/Bloomsbury Rheumatology Unit, Department of Medicine and Department of Haematology, University College London, London, UK.

The ability of an anti-phospholipid (LJ1) and an anti-beta2-GPI (RSP-57) human MoAb to bind to apoptotic but not viable cells was demonstrated in this study. Both MoAbs were derived from patients with systemic lupus erythematosus and anti-phospholipid antibody syndrome. The parallel analysis of the specificity and affinity of four anti-phospholipid human MoAbs suggests that the binding of LJ1 MoAb to apoptotic cells is a specific property of this MoAb. RSP-57 MoAb recognizes apoptotic cells through beta2-GPI which becomes available for binding after the interaction with negatively charged phospholipids. This observation provides evidence that the binding of human anti-phospholipid antibodies to apoptotic cells occurs in both a beta2-GPI-dependent and independent way and involves a restricted group of epitopes. The finding that LJ1 and RSP-57 MoAbs bind apoptotic cells underlines the property of these MoAbs to act as cell membrane markers of apoptosis. Major pathological implications derive from the observation that LJ1 and RSP-57 MoAbs recognize epitopes expressed on 'early' apoptotic cells. The interference with the in vivo clearance and processing of apoptotic cells is a potential pathogenic mechanism of these antibodies.

UI MeSH Term Description Entries
D008563 Membrane Lipids Lipids, predominantly phospholipids, cholesterol and small amounts of glycolipids found in membranes including cellular and intracellular membranes. These lipids may be arranged in bilayers in the membranes with integral proteins between the layers and peripheral proteins attached to the outside. Membrane lipids are required for active transport, several enzymatic activities and membrane formation. Cell Membrane Lipid,Cell Membrane Lipids,Membrane Lipid,Lipid, Cell Membrane,Lipid, Membrane,Lipids, Cell Membrane,Lipids, Membrane,Membrane Lipid, Cell,Membrane Lipids, Cell
D010743 Phospholipids Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system. Phosphatides,Phospholipid
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody
D017152 Antibodies, Antiphospholipid Autoantibodies directed against phospholipids. These antibodies are characteristically found in patients with certain autoimmune diseases (e.g., SYSTEMIC LUPUS ERYTHEMATOSUS and ANTIPHOSPHOLIPID SYNDROME), some non-autoimmune diseases, and also in healthy individuals. Antiphospholipid Antibodies,Antiphospholipid Autoantibodies,Antiphospholipid Autoantibody,Phospholipid Autoantibodies,Phospholipid Autoantibody,Antiphospholipid Antibody,Antibody, Antiphospholipid,Autoantibody, Antiphospholipid,Autoantibody, Phospholipid
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis

Related Publications

V Pittoni, and C T Ravirajan, and S Donohoe, and S J MacHin, and P M Lydyard, and D A Isenberg
June 2000, Clinical and experimental immunology,
V Pittoni, and C T Ravirajan, and S Donohoe, and S J MacHin, and P M Lydyard, and D A Isenberg
October 1998, Journal of autoimmunity,
V Pittoni, and C T Ravirajan, and S Donohoe, and S J MacHin, and P M Lydyard, and D A Isenberg
October 1998, Journal of autoimmunity,
V Pittoni, and C T Ravirajan, and S Donohoe, and S J MacHin, and P M Lydyard, and D A Isenberg
January 1998, Lupus,
V Pittoni, and C T Ravirajan, and S Donohoe, and S J MacHin, and P M Lydyard, and D A Isenberg
November 2006, Autoimmunity reviews,
V Pittoni, and C T Ravirajan, and S Donohoe, and S J MacHin, and P M Lydyard, and D A Isenberg
August 2003, Arthritis and rheumatism,
V Pittoni, and C T Ravirajan, and S Donohoe, and S J MacHin, and P M Lydyard, and D A Isenberg
September 1999, Clinical and experimental immunology,
V Pittoni, and C T Ravirajan, and S Donohoe, and S J MacHin, and P M Lydyard, and D A Isenberg
August 2001, Thrombosis and haemostasis,
V Pittoni, and C T Ravirajan, and S Donohoe, and S J MacHin, and P M Lydyard, and D A Isenberg
February 1996, Internal medicine (Tokyo, Japan),
V Pittoni, and C T Ravirajan, and S Donohoe, and S J MacHin, and P M Lydyard, and D A Isenberg
January 1999, Clinical and experimental immunology,
Copied contents to your clipboard!